MIONEVRASI
ItalyIt is used to treat deficiency states of vitamins B1, B6, and B12 and related diseases, such as deficiency polyneuritis, neuritis caused by isoniazid treatment, and alcoholic neuropathies. It is also used as support for neuritis not related to vitamin deficiencies and for trigeminal and sciatic neuralgia.
Frequently asked questions
How should Mionevrasi be taken?
The dose is 1 ampoule per day, to be administered intramuscularly. The doctor may decide to increase the dose in particular cases and must determine the duration of the treatment.
When should you not use this medicine?
It must not be used in case of hypersensitivity (allergy) to one or more components of the product.
What are the side effects of Mionevrasi?
Rarely, sensitization reactions to vitamin B12 have been reported, such as skin rashes, diarrhea and, in exceptional cases, anaphylactic manifestations.
Are there any special precautions to follow?
Injectable preparations containing vitamin B1 should be used with caution in those who have had previous reactions to drugs or suffer from allergic diseases such as bronchial asthma, urticaria, or angioedema. There are no specific contraindications indicated for pregnancy or breastfeeding.
Does the product interact with other medicines?
Particular caution should be exercised if the product is prescribed together with levodopa, used for the therapy of Parkinson's disease.
Instructions for use
Mionevrasi
powder and solvent for injectable solution
Vitamins B 1 + B 6 + B 12
Composition
1 vial of lyophilisate contains: cyanocobalamin (Vit. B12) 1 mg, pyridoxine hydrochloride (Vit. B6) 100 mg, cocarboxylase (Vit. B1) 38.20 mg.
Excipients: glycine.
1 vial of solvent contains: lidocaine hydrochloride 10 mg, water for injections q.s. to 3 ml.
Pharmaceutical form and pack sizes
Powder and solvent for injectable solution. For intramuscular use.
Pack containing 5 vials of lyophilisate + 5 vials of solvent.
Pharmacotherapeutic category
Multivitamin.
Name and address of the Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder: Teofarma S.r.l. – Via F.lli Cervi, 8 – 27010 Valle Salimbene (PV).
Manufactured and controlled by: Teofarma S.r.l. – Viale Certosa, 8/A – 27100 Pavia
Indications
Deficiency states of Vitamins B1, B6, B12 and related conditions, such as: nutritional polyneuritis, neuritis during isoniazid treatment, alcoholic neuropathies.
Supportive therapy in neuritis not related to vitamin deficiency and in trigeminal and sciatic neuralgias.
Contraindications
Hypersensitivity to one or more components of the product.
Special precautions for use
Injectable preparations containing vitamin B1 or its derivatives must be administered with caution in patients with a history of drug reactions or other allergic diseases (bronchial asthma, urticaria, angioedema, etc.).
There are no particular contraindications for the use of this product during pregnancy or breastfeeding.
Interactions with other medicinal products
Particular caution should be exercised when this product is prescribed concomitantly with levodopa for the treatment of Parkinson's disease.
Dosage and method of administration
1 vial daily by intramuscular injection. In specific cases, the dosage may be increased according to the physician’s judgment.
The duration of treatment must be determined by the physician.
Overdose
No cases of overdose have been reported.
Undesired effects
Rarely, cases of hypersensitivity reactions to vitamin B12 have been reported, such as cutaneous and subcutaneous eruptions, diarrhea, and very rarely anaphylactic reactions.
Patients are advised to consult a physician or pharmacist if any unexpected adverse effects occur not listed in this leaflet.
Storage conditions
Caution: Do not use the medicinal product after the expiry date stated on the packaging.
Date of the most recent revision of the leaflet
June 2010
MEDICINAL PRODUCTS MUST BE KEPT OUT OF THE REACH OF CHILDREN
The original data is available in the language of the country of manufacture.
Data source: Italian Medicines Agency (AIFA)
Data last verified: September 21, 2026